VedaBio has secured CRISPR diagnostic intellectual property rights from Mammoth Biosciences to advance its amplification-free syndromic point-of-care molecular diagnostic platform. Leveraging a single ribonucleoprotein system and CRISPR Cascade technology, VedaBio aims to enhance testing speed, reduce costs, and improve sensitivity for rapid pathogen detection. Collaborations with academic labs further underscore its commitment to scalable, accurate diagnostics using CRISPR-based multiplex approaches.